Patients in the higher baseline PSA groups were more likely to be taking 5-ARIs and α-1 antagonist medications at baseline, to have seen a urologist in the prior year, and to have a history of benign prostatic hypertrophy. Here, KLK3 is linked to benign prostatic hyperplasia.